posted
GOVX -- GeoVax Labs, Inc. Com ($0.001) COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
GeoVax Announces Start of 2 New HIV/AIDS Vaccine Human Trials
ATLANTA, July 17, 2007 /PRNewswire-FirstCall via COMTEX/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company, announced an early start of 2 new AIDS vaccine clinical (human) trials. These FDA compliant trials were previously scheduled to start later in 2007 and are the 3rd and 4th in a 4 clinical trial series intended to evaluate both human safety and immune responses to GeoVax's HIV/AIDS vaccines. GeoVax's vaccines are designed to prevent Acquired Immunodeficiency Disease ("AIDS") in humans caused by the virus known as HIV-1 (Human Immunodeficiency Virus), by vaccinating individuals with its DNA and MVA vaccines prior to infection with the virus.
Starting April 2006, the 1st of these 4 human trials evaluated a low dose (1/10th of the vaccine dose) vaccination program. Preliminary results from this blinded trial demonstrated excellent vaccine safety and positive anti- HIV-1 immune responses to the vaccine in 9 of 11 participants where 9 people received GeoVax HIV/AIDS vaccines and 2 received placebos. All trial participants were normal healthy individuals. Final results will be compiled for later public release.
The 2nd of 4 human trials, initiated September 2006, was designed to evaluate results from full dose administration of GeoVax HIV/AIDS vaccines. Recent data indicates excellent safety in this full dose trial. Additional results from ancillary testing conducted at Emory University by Dr. Harriet Robinson demonstrated positive anti-HIV-1 immune responses in the majority of vaccine recipients. Official immune response data will be available later this year.
Excellent results from the 1st and 2nd trial of this 4 trial series have allowed the accelerated start of human trials #3 and #4. These trials began more than a month earlier than originally anticipated.
Due to exceptionally good results, GeoVax's scientific team believes its vaccine may perform equally as well in trial #3 which administers fewer vaccine doses and trial #4 which utilizes only GeoVax's MVA vaccine. "Success in these trials could lead to a simpler vaccine regime making it easier to vaccinate people," stated Dr. Harriet Robinson, PhD., GeoVax's Co-founder and Scientific Advisory Board Chairperson.
Don Hildebrand, GeoVax CEO/President/Co-founder, commented, "We are pleased with the results obtained to date from our ongoing full dose vaccine human trial. The excellent vaccine safety profile demonstrated was key to accelerating the start date of these new human trials. Equally important are the positive immune responses observed in people receiving only 1/10th of a dose of our vaccines. This is very encouraging news."
These human trials, utilizing GeoVax's AIDS vaccines, are conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to the development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the clinical evaluation of GeoVax's DNA and MVA vaccines was also funded and supported by the National Institutes of Health and National Institute of Allergy and Infectious Diseases.
About GeoVax Labs, Inc.
GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.
GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines: - Protected 22 of 23 (96%) non-human primates for over 3-1/2 years post- infection with an AIDS causing virus - 5 of 6 non-vaccinates controls died of AIDS - Are manufactured and tested under GMP/GLP - EMEA and FDA guidelines - Satisfactorily completed early Phase 1 human clinical trial for DNA HIV/AIDS vaccine - Are currently in 2 ongoing human trials started in 2006 with positive immune responses reported in the majority of vaccine recipients as well as good vaccine safety - Recently began 2 additional human trials with a large Phase 2 trial in planning stages for 2008
Safe Harbor Statement All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Companies Securities and Exchange Commission filings and reports.
SOURCE GeoVax Labs, Inc.
-------------------- Pennies are for trading. Posts: 82 | From: dixon ca us | Registered: Jun 2004
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Officers: Donald G. Hildebrand, Chairman/CEO; Andrew Kandalepas, Vice Chairman/Vice President; Mark Reynolds, CFO
Fiscal Year End: December 31
Edgar Filing Status: Current EDGAR Filer
CIK: 0000832489
Outstanding Shares: 712,834,703 as of 2007-03-23
Estimated Market Cap: Not Available Number of Shareholders of Record: 1,300 as of 2007-03-28
Company Notes: Note=1-95 Company filed petition under Chapter XI of the Federal Bankruptcy Code. 5-96 Court approved Plan of Reorganization. 7-96 Company released from Chapter XI bankruptcy proceedings Formerly=Successo, Inc. to 4-91 Formerly=Dauphin Technology, Inc. until 10-06
Transfer Agent: American Stock Transfer & Trust Company, New York, NY 10038
10/11/2006 10/12/2006 DNTK Dauphin Technology, Inc. Common Stock GOVX GeoVax Labs, Inc. Common Stock
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
we'll see where this goes wavechaser. I flipped this last year when it was DNTK. Nice steady swings here imo. Cheers.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Emory University researchers working on a vaccine for the AIDS virus BTW: (Emory University owns 31% of the O/S.)
Web Editor: Keith Whitney Last Modified: 3/8/2007 7:49:17 AM
The world could have a new vaccine designed to kill the AIDS virus in as little as three to four years according to an Atlanta-based group working on the vaccine.
It is a scientific advance that could save tens of millions of lives , and it is being developed on the campus of Emory University.
The work has been going on quietly for the last 15 years . But now it appears headed for the bell lap in the race to prevent the disease.
And the Atlanta-based group may be way ahead of the rest of the world.
The GeoVax lab at Emory is smaller than many garages. And yet the small modular building may be where the battle to end the reign of one the world's biggest killers could be won with a vaccine to prevent AIDS.
"We're getting results back that indicate we're getting very strong immune responses in these individuals these people who received our vaccine," said Don Hildebrand, the president and CEO of GeoVax Inc., the company spearheading the research in collaboration with Emory, the Centers for Disease Control, and the National Institutes of Health.
The vaccine uses a decoy virus with some of the genetic material of the aids virus but not enough for anyone to ever get the disease itself from the shot, according to Dr. Harriet Robinson, Ph. D., of the Emory Vaccine Center.
"It exposes your immune system to a pathogen like a virus or bacteria so before you've seen it you set up memory cells,” Dr. Robinson said, “and then these memory cells mobilize should you get the actual infection."
The test trials have been so successful that the vaccine is now more than a year ahead of schedule.
"Actually another two trials are starting later this year using different combinations of our vaccine and different administration programs,” said GeoVax CEO Hildebrand. “And following that presuming everything goes well we'll be starting a phase two program at the end of the year."
The vaccine works using a one-two pharmaceutical punch to prime the body then kill the virus.
“It raises both antibodies that can block the virus and it raises white blood cells called t cells that can kill the virus infected cells,” said Dr. Robinson. “So it really has two methods of controlling an HIV/AIDS infection once it enters the body."
The vaccine’s success with the simian AIDS virus has been nothing short of remarkable. Not only did the vaccine prevent the infection, it kept it under control for the monkeys that already had it, putting it in a kind of remission.
Researchers believe the same benefits await human subjects.
Website www.geovax.com Click on: News Room/Corporate News/ Media Coverage.
posted March 13, 2007 00:12 -------------------------------------------------------------------------------- AS was: 850,000,000 On 6/29/2006 OS was: 708,326,669 On 11/11/2006 (Emory University owns 31% of the O/S.)
GeoVax Labs, Inc. 1256 Briarcliff Road N.E Emtech Bio Suite 500 Atlanta, GA 30306 United States
Phone: 404-727-0971 Andrew J. Kandalepas, CEO
Management
Andrew J Kandalepas SVP/VCB Donald G Hildebrand PR/CEO/CB/FND Mark W. Reynolds CFO/SEC
SIC Number: 2834 Fiscal Year End: 12-31 Industry: Drugs Transfer Agent: American Stock Transfer & Trust Company CIK: 832489
-------------------- "Nothing in the world is more dangerous than sincere ignorance and conscientious stupidity"
Member Rated: posted March 13, 2007 00:17 -------------------------------------------------------------------------------- up big id like to see a pull back or a .35-.45 botttom before i jump in. what i dont get is that the last news was in early februar
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
doesn't quite look like it's ready yet imo. a lil bit here and there. After this lil spike may pull back again. need to look deeper into mcnally and friends.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Last Trade: 0.3450 Trade Time: 1:53PM ET Change: 0.0350 (11.29%)
jiggle, just needs a bit of love!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
GeoVax Signs a $7.5 Million Private Placement Agreement Tuesday July 31, 3:46 pm ET Investment Supports GeoVax AIDS Vaccine Development
ATLANTA, July 31 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX - News), an Atlanta-based biotechnology company developing human AIDS vaccines, today announced that it has entered into a definitive agreement with PURE Capital LLC, a newly formed investment subsidiary of an established private investment firm, for the sale of $7.5 million of GeoVax common stock. Under the terms of the financing, the investment will be made in two closings to occur on August 6 and on November 5. The investor will also receive warrants to purchase additional shares of GeoVax common stock. Don Hildebrand, GeoVax CEO, President and CEO, stated, "We are exceptionally pleased with the positive response to our progress at GeoVax as reflected by this financing. This major investment by an institutional investor greatly enhances our AIDS vaccine development and human trials program. The $7.5 million funding allows us to push forward into larger scale Phase 2 human clinical trials (AIDS prevention), involving substantially more human participants, and the potential commencement of our therapeutic (AIDS treatment) clinical trials currently under consideration."
Summary of Private Placement Terms are as follows:
* First Closing - $3.5 million (22,580,645 shares) scheduled for closing on August 6, 2007. * Second Closing - $4.0 million (25,806,452 shares) scheduled for closing on Nov. 5, 2007. * At the time of the First Closing, the investor will receive a warrant (First Warrant) to purchase an additional 18,333,333 shares of GeoVax common stock at an exercise price of $0.33 per share and a 3 year exercise period. Provided the investor exercises his right to convert the First Warrant into GeoVax common shares within the 3 year exercise period, an additional $6,050,000 shall be paid to GeoVax. * At the time of the Second Closing, the investor will receive a warrant (Second Warrant) to purchase an additional 16,666,667 shares of GeoVax common stock at an exercise price equal to the closing market price on the day immediately preceding the Second Closing. Therefore, additional proceeds to GeoVax arising from the investor's potential exercise of the Second Warrant can not be determined at this time. * GeoVax granted the investor only "piggyback" registration rights as to all the shares subject to the agreement (including shares underlying the warrants). Therefore, all shares to be issued under the agreement will be subject to SEC Rule 144 holding period requirements, resulting in a one year restriction from trading from the date the shares are acquired by the investor. Should GeoVax file a registration statement in an underwritten public offering, the investor may require GeoVax to include their shares in the registration (subject to certain conditions).
"We have selected this particular investment package over other potential opportunities presented to us because of the more favorable terms associated with this transaction, including but not limited to registration requirements beneficial to GeoVax and protection of the integrity of previous investments in the company," further commented Don Hildebrand.
In addition to the Phase 2 trials being planned for 2008, GeoVax currently has four (4) human trials underway. As recently announced, early positive immune responses from the first two (2) trials allowed the accelerated start of human trials number 3 and 4 in June 2007. These trials began more than a month earlier than originally anticipated. "Success in these trials could lead to a simpler vaccine regime making it easier to vaccinate people," stated Dr. Harriet Robinson, Ph.D., GeoVax Scientific Advisory Board Chairperson.
About GeoVax Labs, Inc.
GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.
GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines:
* Protected 22 of 23 (96%) non-human primates for over 31/2 years post- infection with an AIDS causing virus - 5 of 6 non-vaccinates controls died of AIDS * Are manufactured and tested under GMP/GLP - EMEA (EU) and FDA guidelines * Satisfactorily completed early Phase 1 human clinical trial for DNA HIV/AIDS vaccine * Are currently in 2 ongoing human trials started in 2006 with positive immune responses reported in the majority of vaccine recipients as well as good vaccine safety * Recently began 2 additional human trials with a large Phase 2 trial in planning stages for 2008
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference ATLANTA, Sept. 12 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced the presentation of successful human trial results for its HIV/AIDS vaccines at the AIDS Vaccine 2007 Conference held August 20-23, 2007 in Seattle, Washington.
GeoVax HIV/AIDS human trial results were presented by Dr. Paul Goepfert, MD in a talk 'HIV-1 DNA Prime followed by Recombinant MVA Boost is Well Tolerated and Immunogenic When Administered to Healthy Seronegative Adults.' Dr. Goepfert, from the University of Alabama-Birmingham, is Protocol Chair of HVTN 065, a series of human clinical trials currently evaluating GeoVax's HIV/AIDS vaccine.
GeoVax HIV/AIDS vaccine trial data was presented to over 900 AIDS researchers at the week long conference. Conference Chair, Dr. Lawrence Corey stated, 'It has become clear that a preventative vaccine is essential to controlling the global AIDS epidemic.' The AIDS Vaccine 2007 Conference was organized under the guidance of the Global HIV Vaccine Enterprise, an alliance of independent global organizations dedicated to accelerating preventative AIDS vaccine development.
The conference reported the AIDS epidemic continuing as a global threat with the disease increasing in every region of the world, especially East and Central Asia and Eastern Europe where AIDS incidence was 21% higher in 2006 than in 2004.
Key GeoVax HIV/AIDS Vaccine Human Trial conclusions presented at the AIDS Vaccine 2007 Conference included:
-- GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti- HIV/AIDS immune responses) at both low (1/10th) dose and full doses. -- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants. -- 80% of both the low and full dose trial participants responded to the vaccine which stimulated highly desirable anti-HIV T-cell (white blood cell) and antibody responses. -- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose. -- 2nd MVA vaccination positively increased the number of CD8 T cell responders and antibody responders. -- Excellent results led to authorization to start two new trials with GeoVax HIV/AIDS vaccines which began in June 2007.
These human trials, utilizing GeoVax's HIV/AIDS vaccines, are conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to the development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the clinical evaluation of GeoVax's DNA and MVA vaccines was also funded and
supported by the NIH National Institute of Allergy and Infectious Diseases (NIAID).
About GeoVax Labs, Inc. (www.geovax.com)
GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.
GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines: -- Uses DNA for priming the vaccine responses and recombinant MVA to boost the vaccine response (DNA/MVA vaccine) -- Protected 22 of 23 (96%) non-human primates for over 3-1/2 years post- infection with an AIDS causing virus - 5 of 6 non-vaccinated controls died of AIDS within the 1st year of infection. These trials used a prototype SIV/HIV vaccine for the HIV vaccine that is being advanced in human trials -- Are manufactured and tested under GMP/GLP - EMEA (EU) and FDA guidelines -- Satisfactorily completed early Phase 1 human clinical trials for a DNA HIV/AIDS vaccine -- Are currently in 4 ongoing human trials started in 2006 with positive immune responses reported in the majority of vaccine recipients as well as good vaccine safety -- Are in planning stage for a larger Phase 2 trial tentatively scheduled for 2008
For further information, contact Donald Hildebrand or Jennifer Nelms at (404) 727-0971 or visit www.geovax.com.
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Companies Securities and Exchange Commission filings and report.
posted
U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program
ATLANTA, Sept. 26 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced receipt of an estimated $15,000,000 Integrated Preclinical/Clinical AIDS Vaccine Development [IPCAVD] Grant to support its HIV/AIDS vaccine program.
This large Grant was awarded by the National Institutes of Health-National Institute of Allergy & Infectious Disease [NIH-NIAID], an agency of the U.S. Government. Funding commences October 2007.
Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award. Candidate companies are highly scrutinized and must supply substantial positive AIDS vaccine data to support their application. IPCAVD grants are awarded on a competitive basis and are designed to support later stage vaccine research, development and human trials.
GeoVax will utilize this funding to further its HIV/AIDS vaccine development, optimization, production and human clinical trial testing including Phase 2 human clinical trials planned for 2008.
Dr. Harriet Robinson, Chief Scientific Advisor for GeoVax, guided development of the IPCAVD proposal and will lead a major part of its related studies. Dr. Robinson stated, "This grant will allow GeoVax to move forward our AIDS vaccine evaluation program more efficiently and more rapidly."
"Our selection as a grant recipient is a validation of our vaccine technology, scientific program, success in human trials to date and future strategies," said GeoVax President/CEO, Don Hildebrand. "This $15 million in funding will support additional AIDS vaccine studies as well as expansion of our scientific team at GeoVax."
About GeoVax Labs, Inc. (http://www.geovax.com)
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.
GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
GeoVax DNA and Recombinant MVA HIV/AIDS vaccines: -- Use DNA vaccines to "prime" immune responses and MVA vaccines to "boost" immune responses against the AIDS virus -- Vaccinate against more than 50% of AIDS virus components and can not cause AIDS -- Protected 22 of 23 (96%) non-human primates for over 3 1/2 years post-infection with an AIDS inducing virus. Five of six non-vaccinated controls died of AIDS within the 1st year of infection. These trials used a prototype SIV/HIV vaccine for the HIV vaccine that is being advanced in human trials -- Are manufactured & tested under GMP/GLP - EMEA (EU) and FDA guidelines -- Satisfactorily completed earlier DNA HIV/AIDS vaccine Phase 1 human trial -- Are currently being tested in 4 Human Trials. Two started in 2006, two in summer 2007 -- Have been demonstrated safe to date in human trials -- Are demonstrating positive immune responses against HIV in majority of vaccine recipients -- Are in planning stage for a larger Phase 2 human trial in 2008
For further information, contact Don Hildebrand or Jennifer Nelms at (404) 727-0971 or visit http://www.geovax.com.
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company's Securities and Exchange Commission filings and report.
SOURCE GeoVax Labs, Inc.
CONTACT: Don Hildebrand or Jennifer Nelms, both of GeoVax Labs, Inc., +1-404-727-0971; or Media, Tim Grace, +1-312-640-6667, or Phil Nourie, +1-212-827-3760, both of Financial Relations Board, for GeoVax Labs, Inc. Web site: http://www.geovax.com
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Wink]](wink.gif)
![[Cool]](cool.gif)
